

Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 19, 2019, Curtis Oltmans notified Array that he will be resigning as Executive Vice President, General Counsel and Secretary of Array (“General Counsel”). Mr. Oltmans’s last day of employment with Array will be March 19, 2019. Mr. Oltmans’s resignation did not arise from any disagreement on any matter relating to Array’s operations, policies or practices.

Array’s Board of Directors has appointed Rogan P. Nunn as interim General Counsel effective February 19, 2019. Mr. Nunn will serve as Array’s interim General Counsel pursuant to an agreement with Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, where Mr. Nunn is a Senior Associate specializing in corporate law, securities law, corporate governance, mergers and acquisitions and complex transactions. Previously, Mr. Nunn held positions at Morgan Stanley and KPMG, LLP. Mr. Nunn holds a Bachelor of Science in Finance and International Business from Georgetown University and a Juris Doctor from the University of Virginia School of Law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 20, 2019 Array BioPharma Inc.

By: /s/ JASON HADDOCK
Jason Haddock
Chief Financial Officer